<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01606436</url>
  </required_header>
  <id_info>
    <org_study_id>12676</org_study_id>
    <secondary_id>H8Y-MC-HBCG</secondary_id>
    <nct_id>NCT01606436</nct_id>
  </id_info>
  <brief_title>A Study Measuring Effect of Pomaglumetad Methionil (LY2140023) on Electrocardiographs in Participants With Schizophrenia</brief_title>
  <official_title>A Placebo- and Positive-Controlled Study of the Electrophysiological Effects on the QT Interval After a Supratherapeutic Dose of LY2140023 in Subjects With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine if a single dose of pomaglumetad methionil affects the electrical
      activity in the heart in people with schizophrenia. This study will also help determine how a
      single high dose of pomaglumetad methionil is tolerated by participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline up to 12 hours post dose in QT interval corrected for heart rate (QTc)</measure>
    <time_frame>Baseline, up to 12 hours post dose in each treatment period</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Schizophrenic Disorders</condition>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matching pomaglumetad methionil administered orally once during 1 of 3 crossover periods, separated by a 2 day washout period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>400 mg pomaglumetad methionil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg pomaglumetad methionil administered orally once during 1 of 3 crossover periods, separated by a 2 day washout period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>400 mg Moxifloxacin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Positive control, unblinded moxifloxacin administered orally once during 1 of 3 crossover periods, separated by a 2 day washout period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomaglumetad methionil</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>400 mg pomaglumetad methionil</arm_group_label>
    <other_name>LY2140023</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching placebo</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Sugar pill</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>400 mg Moxifloxacin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of schizophrenia

          -  Female participants who are postmenopausal

          -  Not hospitalized for psychiatric illness for at least 12 weeks prior to Day 1 of the
             study

          -  Willing and able to be hospitalized from Day 1 to the end of the study

          -  Can be washed out of their antipsychotic medication for the duration of the study

          -  Considered reliable, able to understand, and willing to perform all study procedures

          -  Understand the nature of the study and give written informed consent

          -  Clinical laboratory test results within normal reference range

          -  Venous access sufficient to allow blood sampling

          -  Clinically acceptable sitting blood pressure and heart rate

        Exclusion Criteria:

          -  Currently enrolled in, have completed or have discontinued within the last 30 days
             from a clinical trial involving an investigational drug

          -  Known allergies to pomaglumetad methionil or its active metabolite (LY404039),
             moxifloxacin, related compounds or components

          -  Previously completed this study or prematurely discontinued from any study after
             having received at least 1 dose of pomaglumetad methionil

          -  Received treatment with clozapine

          -  Received aripiprazole within 2 months prior to screening

          -  Taking either thioridazine or thiothixene

          -  Receiving treatment with depot antipsychotic medication within 12 weeks, prior to
             screening

          -  Taking any medications other than those that are specifically permitted in the
             protocol

          -  Asthma needing active beta 2 (B2) agonist within 14 days of the study

          -  Active suicidal ideation with some intent to act, without specific plan or with
             specific plan and intent OR had suicidal behavior such as actual attempt, interrupted
             attempt, aborted attempt, preparatory act or behavior within the past 3 months

          -  Substance dependence or substance abuse (except nicotine and caffeine) within the 6
             months prior to admission

          -  Substance-induced psychosis within 7 days of admission (or at any time during the
             dosing period)

          -  History of 1 or more seizures (with exceptions)

          -  Screening electroencephalogram (EEG) with paroxysmal (epileptiform) activity

          -  Have had electroconvulsive therapy (ECT) within 3 months of Day 1 of the study or who
             are expected to have ECT at any time during the live phase of this study

          -  Parkinson's disease, dementia-related psychosis, or related disorders

          -  Untreated hyperthyroidism or hypothyroidism needing a thyroid hormone supplement who
             have not been on a stable dose of medication for at least 2 months prior to screening

          -  History of leukopenia or agranulocytosis

          -  Alanine aminotransferase/serum glutamic pyruvic transaminase (ALT/SGPT) or aspartate
             aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT) values greater
             than 2 times the upper limit of normal (ULN) or total bilirubin values greater than
             1.5 times the ULN of the performing laboratory at screening

          -  Abnormality in the 12-lead electrocardiogram (ECG) that increases the risks associated
             with participating in the study

          -  Premature ventricular contraction (PVC) associated with symptoms and/or any complex
             PVCs

          -  Heart rhythm disturbance by history or ECG at screening

          -  Personal or family history of long Q wave T wave (QT) syndrome

          -  Family history of sudden unexplained death or cardiac death in a family member under
             60 years of age

          -  Unexplained syncope within the last year

          -  Acute, serious, or unstable medical conditions

          -  Prolactin level of greater than 200 nanograms per milliliter (ng/mL) (200 micrograms
             per liter [ug/L], or 4228 milli-international units per liter [mIU/L]) at screening
             (with the exception of participants treated with risperidone) at screening

          -  Medical history of Human Immunodeficiency Virus positive (HIV+) status

          -  Test positive for (1) Hepatitis C virus antibody or (2) Hepatitis B surface antigen
             (HBsAg) with or without positive Hepatitis B core total antibody

          -  Smoke greater than or equal to 40 cigarettes per day

          -  Movement disorder that could interfere with conducting 12-lead ECGs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri, 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19139</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78754</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2012</study_first_submitted>
  <study_first_submitted_qc>May 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2012</study_first_posted>
  <last_update_submitted>September 28, 2012</last_update_submitted>
  <last_update_submitted_qc>September 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

